Can a Pre-Surgery drug tame metastatic kidney cancer?

NCT ID NCT00715442

Ongoing Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial is studying whether giving the drug sunitinib before surgery to remove a kidney can help control metastatic renal cell carcinoma. About 50 patients with kidney cancer that has spread will take sunitinib for 28 days, then have the affected kidney removed. Researchers are tracking how long it takes for the cancer to progress and any side effects from the drug.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Sunitinib (Sutent), a cancer drug taken by mouth
What this could lead to: If successful, this approach could help control metastatic kidney cancer before surgery, potentially improving outcomes.
What could go wrong: This is a small, early-phase trial with only 50 participants. The drug may cause serious side effects, and it is not yet known if it truly improves survival or disease control.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CLEAR CELL RENAL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

clear cell renal carcinoma renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RENAL CELL CARCINOMA

Contacts and locations

Locations

Baylor College of Medicine

Houston, Texas, 77030, United States
University of Texas MD Anderson Cancer Center

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.